secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001493152-24-017782
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos awaits Nasdaq confirmation on equity compliance; warns of delisting risk if capital insufficient
--------------------------------------------------------------------------------

- Company believes it met $2.5M minimum equity requirement by March 19, 2024, via capital raises in Nov 2023 and Feb 2024.
- Nasdaq has not yet confirmed compliance; will monitor ongoing compliance at next periodic report.
- Company expects to need additional equity capital to maintain compliance; failure could lead to delisting.
- Delisting would materially harm stock price, liquidity, capital raising ability, and reputation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224017782/0001493152-24-017782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224017782/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-017782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer